News & Events
Taubman Prize awarded to Mahlon DeLong, M.D., of Emory University
Clinician-scientist developed Parkinson’s disease breakthrough
Ann Arbor, Mich. — A physician-scientist whose work has improved quality of life for tens of thousands of Parkinson’s disease patients is the recipient of the 2015 Taubman Prize for Excellence in Translational Medical Science, the University of Michigan’s A. Alfred Taubman Medical Research Institute announced.
Mahlon DeLong, M.D., Professor of Neurology at the Emory University School of Medicine, will receive the $100,000 prize in recognition of his contributions to the treatment of Parkinson’s disease.
DeLong’s research – spanning a 40-year career in medicine and science – identified the anatomical brain circuits involved in the clinical features of Parkinson’s disease and a novel target for surgical intervention, the subthalamic nucleus, a portion of the basal ganglia, brain structures located deep in the brain.
This finding paved the way for the application of high frequency deep-brain stimulation (DBS) of the subthalamic nucleus, a technique now used worldwide for advanced Parkinson’s disease patients. More than 100,000 individuals have received the treatment, which suppresses tremor and other motor impairments, and improves the ability to carry out the normal activities of daily living.
“Dr. DeLong’s contribution to improved care and quality of life for patients with devastating movement disorders is remarkable,” said Eva Feldman, M.D., Ph.D., director of the Taubman Institute, and the Russell N. DeJong Professor of Neurology at the U-M Medical School. “He exemplifies the ethos of the dedicated clinician-scientist. We are honored to recognize his extraordinary contributions by awarding him the Taubman Prize.”
DeLong was selected by a national panel of eminent medical science experts from among dozens of nominees for the Taubman Prize. Over decades he and his colleagues have mapped brain activity and deciphered the complex pathways and circuitry involved with the processing of motor functions, thoughts and emotions. Insights gained through his basic research, animal models and experiments eventually led to a clearer understanding of the abnormalities in brain circuits in animal models of Parkinson’s and how interruption of a key portion of the motor circuits could dramatically improve clinical features.
DeLong’s studies contributed greatly to the revival of surgical approaches for treating movement disorders. The development of the novel technique of high frequency deep-brain stimulation, using implanted electrodes, by Dr. Alim Louis Benabid in Grenoble, France, when applied to the subthalamic nucleus in patients with Parkinson’s produced a similar result as surgical interruption. DBS, because of its less invasive, reversible and adjustable features, rapidly replaced direct, irreversible destructive lesioning approaches.
DeLong, the William Timmie Professor of Neurology at Emory University School of Medicine, will present the keynote address at the Taubman Institute’s annual symposium on Oct. 16, 2015 at the Kahn Auditorium on the U-M medical campus. The symposium is open to the general public.
The Taubman Prize was established in 2012 to recognize outstanding translational medical research beyond the University of Michigan. It includes a $100,000 award and is presented each year to the non-U-M clinician-scientist who has done the most to transform laboratory discoveries into clinical applications for patients suffering from disease.
Previous recipients are:
2014: Carl June, M.D., of the Perelman School of Medicine at the University of Pennsylvania, for discoveries related to immunotherapy for leukemia using patients’ own T cells.
2013: Brian Druker, M.D., of the Oregon Health & Science University and Charles Sawyers, M.D., of Memorial Sloan Kettering Cancer Center, for their discoveries related to chronic myeloid leukemia.
2012: Hal Dietz, M.D., of Johns Hopkins University for his discoveries related to connective tissue disease.
About Mahlon DeLong, M.D.: DeLong is a key faculty leader of The Jean and Paul Amos Parkinson's Disease and Movement Disorders Research Program. He also is co-director and founder of ENTICe (Emory Neuromodulation and Technology Innovation Center), whose goal is to foster advancement of neuromodulation and the development of innovative neuromodulation technologies for the treatment of neurological and psychiatric disorders.
He is a member of the Institute of Medicine, a fellow of the American Academy of Arts and Sciences, a fellow of the American Association for the Advancement of Science (AAAS), an elected member of the Johns Hopkins Society of Scholars. He is scientific director of the Dystonia Medical Research Foundation and a member of the Scientific Advisory Board of the American Parkinson Disease Association.
DeLong received his undergraduate degree from Stanford University and his medical degree from Harvard University. He worked as a researcher at the National Institute of Mental Health at the National Institutes of Health (1968-1973) completed his residency in Neurology at Johns Hopkins School of Medicine and was a member of the Johns Hopkins faculty (1975-1989). In 1989 he joined Emory University School of Medicine, where he served as chair of the Department of Neurology (1989-2003).
DeLong has received numerous awards including the 2013 Breakthrough Prize in Life Sciences and the 2014 Lasker Award, which recognizes excellence in research aimed at curing intractable diseases and extending human life. He also received the 2009 American Academy of Neurology Movement Disorders Research Award and the 2008 Movement Disorders Society Lifetime Achievement Award.
He is a member of the Institute of Medicine, a fellow of the American Academy of Arts & Sciences, a fellow of the American Association for the Advancement of Science (AAAS), an elected member of the Johns Hopkins Society of Scholars, and is a past chair of the Society for Neuroscience. He is scientific director of the Dystonia Medical Research Foundation and a member of the Scientific Advisory Board of the American Parkinson Disease Association.
About the A. Alfred Taubman Medical Research Institute: In 2007 Michigan businessman, philanthropist and noted patron of the arts A. Alfred Taubman provided the initial funds to establish the institute bearing his name at the University of Michigan Medical School. Its mission is to provide the university’s finest medical scientists the freedom, resources and collaborative environment they need to push the boundaries of medical discovery, to produce breakthroughs in cures to speed the development of effective treatment for some of the most devastating illnesses. Currently, nearly 40 Taubman Scholars are advancing their research with the assistance of grants from the institute.
Dr. Max Wicha appointed to National Cancer Advisory Board
President Barak Obama announced his selection of Max S. Wicha, M.D., as one of five new appointees to the National Cancer Advisory Board.
Wicha, the Madeline and Sidney Forbes Professor of Oncology at the University of Michigan Comprehensive Cancer Center, will serve on the 18-member board for six years.
“I am honored that these talented individuals have decided to serve our country. They bring their years of experience and expertise to this Administration, and I look forward to working with them,” Obama said in a statement.
The NCAB and the President’s Cancer Panel are the only advisory bodies at either the National Institutes of Health or the Department of Health and Human Services whose members are appointed by the president. The primary task of the NCAB is to advise the secretary of Health and Human Services, the director of the National Cancer Institute, and ultimately the president of the United States on a range of issues affecting the nation’s cancer program and, specifically, NCI operations. The NCAB reviews and recommends grants and cooperative agreements following technical and scientific peer review.
Wicha founded the U-M Comprehensive Cancer Center and served as director for 27 years. He is a renowned cancer researcher who was part of the team that first identified cancer stem cells in a solid tumor, finding them in breast cancer. His lab continues to look at cancer stem cells to help improve treatments for metastatic breast cancer.
Wicha also serves as the deputy director of the A. Alfred Taubman Medical Research Institute.
Art auction helps expand Emerging Scholars Program
Two festive events have led to an expansion of the Taubman Institute's Emerging Scholars Program, said Eva L. Feldman, M.D., Ph.D., director of the institute.
Held in May, "Cures Are an Art Form" and "An Evening of Art + Science" each celebrated collaborations among Taubman Scholars -- U-M's eminent clinician-scientists -- and leading contemporary artists. The artists and scientists met for ab and studio tours, and discussions about the nature of ideas and curiosity and discovery in their respective fields. Then, the artists produced works of creativity inspired by the research of scholars working in fields as diverse as ophthalmology, dermatology, oncology and brain diseases.
The artwork was showcased at "Cures Are an Art Form" at Detroit's new nightclub Populux, and an online auction culminated May 14 during the gala "An Evening of Art + Science" at the Detroit Institute of Arts.
Through the sale of tickets, sponsorships and most importantly the original works of art, the Taubman Institute realized sufficient funds to expand the Emerging Scholars Program, which helps to support the up-and-coming generation of biomedical researchers.
"We are delighted that our second annual Evening of Art + Science was such a success," said Feldman. "Our deepest thanks to all who contributed and attended. I think we all enjoyed the opportunity to contemplate both art and science in new ways, and to enlarge our understanding of the intersection of both worlds. The monies we have raised will go directly to the support of early-career clinician-researchers, keeping the pipeline of new medical breakthroughs full for future generations."
Click here to view the photo gallery.
Science-inspired artwork up for sale!
The Taubman Institute Evening of Art + Science, held May 14 at the Detroit Institute of Arts, was a gala success.
Select artwork, below, still is available for purchase, with proceeds to benefit the Taubman Institute's Emerging Scholars Program. For more information, contact Glen Walker at (734) 615-7282 or
About the Art + Science Collaboration
Twenty physician-researchers of the A. Alfred Taubman Medical Research Institute – global thought leaders in areas like cancer, cardiovascular health, ALS and more – teamed up this year with painters, sculptors, jewelers and other creative virtuosos for mind-bending conversations about the intersection of discovery and creativity in their respective fields.
In visits to one another’s labs and studios, the artists and scientists found common ground in the process each uses to leap challenges, to refine new techniques and to test novel hunches and ideas.
In the laboratory, the process leads to life-giving new treatments and cures. In the studio, the journey of inspiration results in works of beauty and expression. The resulting one-of-a-kind creations — in media ranging from oils to textiles to gemstones — are sold to fund the Taubman Institute's Emerging Scholars grants.
Aimed at launching the laboratories of U-M's best and brightest young doctors, these grants of $50,000 per year for three years help ensure the next generation of medical breakthroughs. In just a few short years, Taubman Emerging Scholars have initiated nine human clinical trials of new treatments in fields ranging from cancer to inflammatory diseases. With 16 Emerging Scholars now being supported – and two dozen more worthy candidates vetted and ready for funding – it’s a program that aims for, and achieves, fast results for patients who can’t wait.
Ch. 4 covers institute's unique art + science program
Detroit's WDIV television station (Ch. 4) interviews Taubman Scholar Tom Gardner, M.D., M.S., and artist Osman Khan, who recently teamed up as part of the Taubman Institute's annual artist-scientist collaboration.
Along with 19 other scholar-artist pairs, Gardner and Khan discussed the similarities between research and artistic creation. The resulting artworks were auctioned May 14 at An Evening of Art + Science to raise funds for the institute's Emerging Scholars Program, which supports early-career clinician-scientists.
Click here to view the WDIV report.
Taubman Scholar develops improved test for prostate cancer
Use of Mi-Prostate Score would reduce unneeded biopsies
Research led by Taubman Emerging Scholar Scott Tomlins, M.D., Ph.D., has led to a new urine-based test providing improved prostate cancer detection – including detecting more aggressive forms of prostate cancer – compared to traditional models based on prostate serum antigen, or PSA, levels.
The test, developed at the University of Michigan Comprehensive Cancer Center, is called Mi-Prostate Score, or MiPS. It combines PSA with two markers for prostate cancer, T2:ERG and PCA3, both of which can be detected through a urine sample. The test has been available clinically since September 2013.
“Around 50 percent of men who undergo a prostate biopsy will not have cancer. We need better ways to manage elevated PSA and determine who really needs to have a biopsy. MiPS gives men and their doctors better information to help make those decisions,” says lead study author Tomlins, assistant professor of pathology and urology at the University of Michigan Medical School.
The study looked at a total of 1,977 men who were undergoing prostate biopsy because of elevated PSA levels. Using urine samples, the researchers conducted MiPS testing and compared results to various combinations of PSA, PCA3, T2:ERG and other PSA-based risk calculators. They assessed how well the individual biomarkers and combinations of biomarkers predicted the likelihood of cancer and the likelihood of high-risk cancer – the aggressive type that needs immediate treatment.
The test reports individual risk estimates for prostate cancer and high grade cancer. Each patient’s personal threshold for choosing to undergo biopsy may vary, so there is no single cutoff for a “positive” result.
However, using one MiPS cutoff score to decide whether to biopsy patients would reduce the number of biopsies by one-third, while delaying the diagnosis of only about 1 percent of high-risk prostate cancers. The study is published in European Urology.
“MiPS gives men a more individualized risk assessment for prostate cancer, so that men concerned about their serum PSA levels can have a more informed conversation with their doctor about next steps in their care,” Tomlins says. A cost/benefit analysis of MiPS is being conducted.
PCA3 is approved by the U.S. Food and Drug Administration for prostate cancer risk assessment in men with a previous negative biopsy. Most of the men involved in this study were undergoing initial biopsy, suggesting MiPS can be useful earlier in the process.
The test is part of broader efforts at the University of Michigan to improve prostate cancer diagnosis, particularly detecting the type of cancer that requires immediate and aggressive treatment.
Mi-Prostate Score is available to anyone but requires a request from a doctor. For further information, call the University of Michigan's MLabs at 800-862-7284. Patients with questions about prostate cancer detection or treatment may call the U-M Cancer AnswerLine at 800-865-1125.
Information for those wishing to make a donation
At the Taubman Institute, we have been deeply touched by the calls and e-mails from individuals wishing to honor the life and legacy of A. Alfred Taubman through a donation to support lifesaving medical research.
To make a gift online via credit card, simply click here.
Checks made payable to the University of Michigan may be mailed to:
A. Alfred Taubman Medical Research Institute
109 Zina Pitcher Place
5017 A. Alfred Taubman Biomedical Science Research Bldg.
Ann Arbor, MI 48109-2200
For assistance, please phone: 734-615-7282
The University of Michigan has 501(c)(3) non-profit tax exempt status; our federal tax ID number is 38-6006309.
Our deepest thanks to all who have extended condolences and memorial tributes on the passing of Mr. Taubman.
Taubman Scholars reflect on A. Alfred Taubman
The mission of the Taubman Institute is to support eminent clinician-scientists — doctors taking on the dual role of physician and laboratory researcher in their zeal to speed new cures and treatments to their patients.
Taubman Scholar grants allow these dedicated healers the freedom they need to pursue “high-risk, high-reward” science that in a few short years has led to more than 50 human clinical trials of new therapies.
Here, the Taubman Scholars share their reflections on the extraordinary contributions that Alfred Taubman has made to the future of medical science.
The Taubman Institute that is the refection of Mr. Taubman’s unselfishness has enabled a line of scientific inquiry that would not have occurred otherwise. Mr. Taubman and I had two one-on-one conversations, the first when he came to my office to consider my application as a Scholar, and the second more recently. On both occasions he inspired me with his determination, forward looking approach and kindness. I am forever grateful to have had the chance to know him and his family.
Thomas Gardner, M.D., M.S.
Healthy Eyes Taubman Scholar
Professor, Ophthalmology and Visual Sciences
Professor, Molecular and Integrative Physiology
Director, Juvenile Diabetes Foundation Retinopathy Center
To me, the Taubman Institute represents a celebration of a life well-lived, and a deep desire to make a difference for the good of the world. Mr. Taubman was always a visionary, striving to invent and reinvent. He was amazingly successful at that. I’m fortunate to have made Mr. Taubman's acquaintance, and am very proud to be part of the Taubman Institute.
Alon Kahana, M.D., Ph.D.
Assistant Professor and Helmut F. Stern Professor
Ophthalmology and Visual Sciences
Kellogg Eye Center, University of Michigan
When one has an inspiration to further high risk, high reward translational science, and operationalizes it, it has the most meaning for those patients who ultimately benefit from that inspiration and kindness. Mr. Taubman’s inspiration has motivated young as well as established scientists to heed his call to provide help for those afflicted with disease. The world is in a better place through that inspiration.
John M. Carethers, M.D.
John G. Searle Professor and Chair
Department of Internal Medicine
Mr. Taubman supported the research in my laboratory. He took the time to listen to me and to encourage the progress we were making towards better treatments for people who were infected with HIV. He helped me and the trainees in my lab. I am grateful for this and I am honored to have known him. He will be greatly missed.
Kathleen Collins, M.D., Ph.D.
Internal Medicine Collegiate Professor of HIV Research
Professor of Internal Medicine
Professor of Microbiology and Immunology
Alfred was a great and inspiring man. The establishment of the Taubman Institute was grounded in his desire to end human suffering from diseases including dementia, Lou Gehrig's disease, and childhood cancer. I am grateful to have met him. His kindness and passion for science to improve the human condition were both inspiring and a great motivator for me and my research team.
Valerie P. Castle, M.D.
Chair, Pediatrics and Communicable Diseases
Ravitz Foundation Professor of Pediatrics and Communicable Diseases
Professor of Pediatric Hematology/Oncology
I got to know Mr. Taubman about four years ago when I was being considered to become a Taubman Scholar. I showed him our work in treating liver tumors with a unique radiation therapy approach and was amazed at how quickly he understood the concepts and of the quality of the questions he asked. He was 100 percent on target and very perceptive.
In addition to his well-known passion for architecture and for building, he had a keen mind and depth of insight well beyond what I would expect from the average intelligent lay person. Maybe it is because radiation therapy depends on three dimensional thinking, and his "architectural brain" was already trained that way.
He will be missed.
Theodore S Lawrence, M.D., Ph.D., FASCO, FASTRO
Max S. Wicha M.D. Distinguished Professor of Oncology
Director, University of Michigan Comprehensive Cancer Center
Chair, Department of Radiation Oncology
Alfred Taubman's vision in creating the Taubman Medical Institute has been transformative. His generosity has allowed us to form the collaborations and pursue the type of high risk-high reward research that is critical to advance our field.
Srijan Sen, M.D., Ph.D.
Psychiatry, Neuroscience and Bioinformatics
Molecular and Behavioral Neuroscience Institute
It is difficult to convey what Mr. Taubman did for me, personally, to push forward new lines of research in my own lab. I was fortunate to have lunch with Mr. Taubman last year at his office, where his curiosity about many things, including science, was on full display – impressive indeed! I saw firsthand his deep commitment to spur Taubman Scholars toward new insights into human disease and, from that knowledge, better therapies. Mr. Taubman made, and will continue to make, a major impact on what many of us do in our labs and at the bedside.
Henry L. Paulson, M.D., Ph.D.
Professor, Department of Neurology
Lucille Groff Professor of Neurology
Some men and women achieve immortality. It may be through the memory and deeds of their children. It may be through the legacy of their work. It may be through the achievements of others that they have made possible.
A. Alfred Taubman, mentor, patron, and friend to so many of us, achieves immortality through each of these. Through the A. Alfred Taubman Medical Institute, which Alfred and his family founded and support, and in which I am a scholar, physician-scientists are finding meaningful treatments for the most difficult neurological diseases of our time—ALS or Lou Gehrig’s disease, Alzheimer’s disease, Parkinson’s disease, spinal cord injury and stroke.
Ongoing initiatives, which helped and continue to help scores of patients with terrible disease, were always front-and-center in our conversations. Alfred’s insightful and incisive questions, his encouragement and support to break through barriers and challenges, and his shared delight in what we have achieved, never failed to inspire. He uniquely provided both the faith that makes the seemingly impossible possible and the critical resources to make it happen.
He has been a giant, on whose shoulders we can all stand. I will miss Alfred as a mentor and as a friend, I will remember him for his curiosity and his warmth and his unwavering support, and my patients will thank him for all that he has made possible, for the rest of our days. For who he has been and for what he has done, A. Alfred Taubman is truly immortal.
Parag G. Patil, M.D., Ph.D.
Assistant Professor of Neurosurgery, Neurology, Anesthesiology, and Biomedical Engineering
I am deeply saddened by our loss of Mr. Taubman. Since the beginning of my academic career in medicine he has inspired me in countless ways. The admiration that I have for him lies not only in his overwhelming support of me and my lab efforts, but by his compassion and his unyielding desire to change to world. I will miss him dearly. His legacy will live on through us all.
Erika Newman, MD, FAAP, FACS
Assistant Professor of Pediatric Surgery
Surgical Director, Mott Solid Tumor Oncology Program (MSTOP)
His vision and tremendous generosity for supporting research has touched many, including me. He has left an indelible legacy here at Michigan and I will personally remember him for his wit, curiosity and genuine interest in knowing about my own and others research. An irreplaceable loss, my heart and prayers go out to his family and loved ones.
Pavan Reddy, M.D.
Moshe Talpaz Professor of Translational Oncology
Professor of Medicine
Co-Director, Hematological Malignancies and BMT Program
Associate Division Chief, Hematology-Oncology
The support from Mr. Tubman and the Emerging Scholars Program has been instrumental in my ability to advance translational research and I am so greatful for his amazing generosity. He will be sorely missed, but his vision for research advancement will live on through all those whom his gifts have touched.
Katherine A. Gallagher, M.D.
Assistant Professor of Surgery
What I felt after all of my interactions with Alfred was his joy of accomplishment. He always seemed to have such a positive attitude. Whether he was talking about his career or the next thing he was going to do in life, there wasn’t a doubt in his mind that he couldn’t do it. It was infectious.
Charles F. Burant, M.D., Ph.D.
Dr. Robert C. and Veronica Atkins Professor of Metabolism
Professor of Internal Medicine
Professor of Molecular and Integrative Physiology
Mr. Taubman was an extraordinary pioneer, innovator and visionary and I had the good fortune to first meet him in 2011 when I joined the Taubman Medical Research Institute as an Emerging Scholar. Of the discussions I’ve had with Mr. Taubman over the years, several of which incidentally were on salmon fishing in my home country Iceland, I have always been struck by his inquisitive mind and openness. Through his vision the work that he has enabled at the Taubman Medical Research Institute will have a world-wide impact in the years and decades to come. Thank you Mr. Taubman for all you have done
Johann Gudjonsson, M.D., Ph.D.
Assistant Professor, Dermatology
Mr. Taubman’s generosity and commitment to the University of Michigan has impacted my every phase of my career, beginning as a medical student studying in the Taubman Library or seeing patients in the Taubman Health Care Center to starting my laboratory in the A. Alfred Taubman Basic Sciences Research Building. More recently, being named the A. Alfred Taubman Emerging Scholar allowed me to get to know Mr. Taubman and experience firsthand his commitment to the University, young clinician scientists, and translational research that can directly impact patients.
Scott Tomlins, M.D., Ph.D.
The A. Alfred Taubman Emerging Scholar
Assistant Professor, Pathology
Dr. Eva Feldman commemorates Alfred Taubman
A. Alfred Taubman, one of the world's leading champions of bold approaches to medical research, passed away at age 91 on April 18, 2015. One of his enduring legacies will be the groundbreaking work of the clincian-scientists whose work has been accelaterated by the charge from the Taubman Institute to use unrestricted financial grants to follow their hunches and establish new paradigms in the development of cures and diseases for mankind's most difficult diseases.
“All of us who knew and worked with Mr. Taubman are deeply grieving his passing. But at the same time we are grateful for his extreme generosity, wise leadership and limitless ability to make change happen,” said Eva L. Feldman, M.D., Ph.D., director of the A. Alfred Taubman Medical Research Institute at the University of Michigan.
“The source of Mr. Taubman’s greatness lies in his bold, visionary thinking and his willingness to take bold risks that changed conventional thinking in every area he touched. The immeasurable benefits his work will bring to future generations will be the legacy of his passion, his inspiration and his unmatched ability to achieve grand results.”
University of Michigan Statement on the passing of A. Alfred Taubman
Statement from Mark S. Schlissel, M.D., Ph.D., president of the University of Michigan
The University of Michigan family was saddened to learn of the passing of A. Alfred Taubman. We have lost a dear friend and educational partner, one of the genuine leaders and best.
Our hearts go out to his family, friends, loved ones, and all those he has touched with his considerable generosity and commitment to a better University of Michigan.
The University of Michigan – and the opportunities we provide to our students – would not be the same without Mr. Taubman. He valued state-of-the-art facilities for teaching, research and patient care, and he was always mindful of supporting the activities that take place inside the university and the buildings that bear his name. He provided scholarships to our students, enhanced the way we teach architecture and urban planning, and gave our faculty the opportunity to launch unparalleled medical research initiatives.
Mr. Taubman’s legacy at the University of Michigan will forever reflect his generosity, impact, and passion for advancing opportunities for our campus, its students and the health and well-being of all members of society. His strong support of the University of Michigan during his life will be further augmented by the provisions he made in his will for the university’s future.
He was a great man– successful, generous and warm. But he also was someone who held all those around him to high standards. He helped drive excellence at Michigan not just through his philanthropy, but by the advice he gave to multiple presidents and the fact that he held us to account to get the very most out of everything we did.
Our entire community will deeply miss Mr. Taubman and his commitment to our campus and students.
Dr. Eva Feldman: Alfred Taubman as mentor, leader, friend
The source of his greatness lay in his willingness to challenge conventional thinking.
WDIV covers institute's art + science program
Ch. 4 report profiles the collaboration between Taubman Scholar Tom Gardner and artist Osman Khan.
Taubman Scholars: Reflections on Alfred Taubman
Eminent scientists say his curiosity, interest and vision changed the course of medical science.
news & events
In the News
Taubman Emerging Scholar makes strides against cancer
Erika Newman, M.D., has identified a characteristic of deadly childhood neuroblastoma that may pave the way for more effective treatments.
Drug cuts risk of bone-marrow transplant side effect
Taubman Emerging Scholar Sung Won Choi, M.D., is the lead author of a new study that finds a new way to help prevent graft-vs-host disease in cancer patients receiving bone-marrow transplants.
Study: Two types of cancer stem cells lead to metastasis
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to a new study published by Taubman Senior Scholar Dr. Max Wicha.